Protocol Ledger

NCT06521866 · Phase II · RECRUITING

Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer

Interventional Phase II clinical trial protocol NCT06521866 sponsored by Fudan University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-01 Enrollment: 208 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06521866
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)208 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06521866
Protocol FieldVerified Registry Value
NCT IdentifierNCT06521866
Consolidated Lead SponsorFudan University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment208 participants (ESTIMATED)
Registered Start Date2025-03-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI